Abstract:A glucose tolerance test (GTT) is routinely used to assess glucose homeostasis in clinical settings and in preclinical research studies using rodent models. The procedure assesses the ability of the body to clear glucose from the blood in a defined time after a bolus dose. In the human clinical setting, glucose is ingested via voluntary consumption of a glucose-sweetened drink. Typically, in the rodent GTT oral gavage (gavage-oGTT) or (more commonly) intraperitoneal injection (IPGTT) are used to administer the glucose bolus. Although used less frequently, likely due to investigator technical and experience barriers, the former is the more physiologically relevant as it integrates the gastrointestinal tract (GI), including release of key incretin hormones. However, orally gavaging glucose in the GTT is also not without its limitations: gavaging glucose straight into the stomach bypasses potentially critical early glucose-sensing via the mouth (cephalic phase) and associated physiological responses. Furthermore, gavaging is stressful on mice, and this by itself can increase blood glucose levels. We have developed and validated a refined protocol for mouse oral GTT which uses a voluntary oral glucose dosing method, micropipette-guided drug administration (MDA), without the need for water deprivation. This approach is simple and non-invasive. It is less stressful for the mice, as evidenced by lower circulating corticosterone levels 10 minutes after glucose-dosing compared to oral gavage. This is significant for animal and investigator welfare, and importantly minimising the confounding effect of stress on mouse glucose homeostasis. Using a randomised cross-over design, we have validated the MDA approach in the oGTT against oral gavage in male and female C57BL/6J and C57BL/6N mice. We show the ability of this method to detect changes in glucose tolerance in diet-induced obese animals. Compared to oral gavage there was lower inter-animal variation in the MDA-oGTT. In addition to being more representative of the human procedure, the MDA-oGTT is easy and has lower barriers to adoption than the gavage oGTT as it is non-invasive and requires no specialist equipment or operator training. The MDA-oGTT a more clinically representative, accessible, and refined replacement for the gavage-oGTT for mouse metabolic phenotyping, which is simple yet overcomes significant deficiencies in the current standard experimental approaches.

Protocol for in Vivo and Ex Vivo Assessment of Hyperglycemia and Islet Function in Diabetic Mice.

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Progress of the Test and Assessment of Islet Β Cell Function

Evaluating insulin secretagogues in a humanized mouse model with functional human islets.

A Practical Guide to Rodent Islet Isolation and Assessment Revisited

Assessment of Insulin Tolerance In Vivo in Mice

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

The Reversal of Hyperglycaemia in Diabetic Mice Using Plga Scaffolds Seeded with Islet-Like Cells Derived from Human Embryonic Stem Cells

A Simplified Streptozotocin-Induced Diabetes Model in Nude Mice

Protocol for xenotransplantation of human skin and streptozotocin diabetes induction in immunodeficient mice to study impaired wound healing

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

In Vivo And In Vitro Characterization Of Insulin-Producing Cells Obtained From Murine Bone Marrow

Pancreas transplantation in the mouse.

A Novel Protocol for Mouse Islet Isolation

Streptozotocin‐Induced Diabetic Models in Mice and Rats

Biomimetic Hydrogels Promote Pseudoislet Formation to Improve Glycemic Control in Diabetic Mice

Validation of a refined protocol for mouse oral glucose tolerance testing without gavage

Proteomic analysis of mouse islets after multiple low-dose streptozotocin injection

An Optical Method to Evaluate Both Mass and Functional Competence of Pancreatic Α- and Β-Cells.

Modelling human diabetes ex vivo: a glance at maturity onset diabetes of the young

A Novel Immunodeficient Hyperglycemic Mouse Carrying the Ins1 Akita Mutation for Xenogeneic Islet Cell Transplantation